In a deal potentially worth $493 million, Alcon has obtained global (excluding US) marketing rights to ThromboGenics ocirplasmin, a potential treatment for symptomatic vitreomacular adhesion (VMA) including macular hole.
Alcon is paying €75 million upfront for the rights. Thrombogenics is also entitled to a €90 million in near-term milestone payments, future milestones of €210 million, and royalties.
Thrombogenics will concentrate on commercializing ocriplasmin in the U.S. where it plans to build its commercial and medical organization to support the product’s anticipated launch within the next 12 months.
Whilst Thrombogenics has relinquished control of development outside the US, it retains 'quids' in that it will still play a strategic and operational role in the commercialization of ocriplasmin in the five largest European markets, enabling it to build the foundation for an expanding ophthalmology franchise.
The deal gives Alcon a new ophthalmology asset for its core business, whilst providing ThromboGenics with funds to continue development in the US market, allowing it to pursue its objective of not only developing novel drugs but also building a commercial activity.
Read the deal story here
View this and other deals at Current Agreements (subscription required)